Latest News for: adoa

Edit

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

Pharmiweb 11 Feb 2026
–Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– ... ADOA is a rare genetic disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life.
  • 1

Article Search

tools
×
×
×
×